ISSN: 1875-6182 (Online)
ISSN: 1871-5257 (Print)


Volume 12, 3 Issues, 2014


Download PDF Flyer




Cardiovascular & Hematological Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Cardiovascular & Hematological Agents

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Debabrata Mukherjee
Department of Internal Medicine Texas Tech University
4800 Alberta Avenue El Paso
Texas, 79905
USA


View Full Editorial Board

Subscribe Purchase Articles Order Reprints


Sodium Glucose Co-Transporter 2 (SGLT2) Inhibition with Canagliflozin in Type 2 Diabetes Mellitus

Author(s): Sarmad Said and German T. Hernandez

Affiliation: Division of Nephrology & Hypertension, Department of Internal Medicine, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center at El Paso, 4800 Alberta Avenue, El Paso, Texas, 79905, USA.

Abstract

The sodium glucose cotransporter 2 (SGLT2) is expressed primarily in the kidneys and is involved in the reabsorption of filtered glucose in the renal tubule. Clinical trials of SGLT2 inhibitors in patients with type 2 diabetes mellitus demonstrate a significant clinical effect in decreasing serum glucose, hemoglobin A1C, body weight, systolic blood pressure, improving β-cell function, and minimizing the risk of hypoglycemia. This report reviews the potentially beneficial effects of SGLT2 inhibitors in type 2 diabetes mellitus, specifically focusing on canagliflozin, the only SGLT2 inhibitor approved for use in the United States.

Keywords: Antihyperglycemic agents, body weight loss, canagliflozin, hypoglycemia, renal threshold for glucose, SGLT2 inhibitor, type 2 diabetes mellitus, urinary glucose excretion.

Purchase Online Rights and Permissions

Article Details

Volume: 11
Issue Number: 3
First Page: 203
Last Page: 206
Page Count: 4
DOI: 10.2174/187152571103140120103032
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science